27,000
Total Claims
$2.2M
Drug Cost
1,607
Beneficiaries
$1,396
Cost/Patient
Peer Comparison vs. 18,720 Cardiology providers
-8%
Cost per patient vs peers
$1,396 vs $1,524 avg
-36%
Brand preference vs peers
8.8% vs 13.7% avg
Brand vs Generic
91% generic
Brand: 2,367 claims · $1.8M
Generic: 24,633 claims · $431K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 1,020 | $982K |
| Rivaroxaban | 274 | $320K |
| Sacubitril/Valsartan | 86 | $83K |
| Empagliflozin | 54 | $77K |
| Evolocumab | 96 | $69K |
| Icosapent Ethyl | 68 | $62K |
| Dapagliflozin Propanediol | 53 | $46K |
| Metoprolol Succinate | 2,353 | $43K |
| Bempedoic Acid/Ezetimibe | 54 | $38K |
| Evolocumab | 37 | $30K |
| Rosuvastatin Calcium | 1,796 | $27K |
| Ranolazine | 197 | $22K |
| Valsartan | 875 | $22K |
| Ezetimibe | 969 | $21K |
| Doxazosin Mesylate | 884 | $19K |
Prescribing Profile
90
Unique Drugs
$1.5M
Patient Profile
74
Avg Age
52%
Female
1.60
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data